Summary & Overview
Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses: Inpatient Reimbursement Overview
DRG 845 addresses inpatient stays for other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without Complication or Comorbidity or Major Complication or Comorbidity. It defines the clinical scope and relative resource use used to determine Medicare inpatient reimbursement for lower-acuity hematology and oncology admissions.
DRG 845 Overview
DRG 845 covers hospital inpatient admissions for patients with other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without a Complication or Comorbidity or a Major Complication or Comorbidity. Clinically this includes primary hematologic proliferative disorders and cases where definitive neoplastic classification is not established during the stay. This Diagnosis-Related Group matters for Medicare payment because it assigns a base payment relative to the expected resources for these less complex hematology oncology admissions. Accurate coding and documentation of diagnosis specificity and comorbid conditions affect grouping and reimbursement.
Clinical Trials
- Trials evaluating novel targeted therapies or immunomodulatory agents for poorly differentiated hematologic malignancies presenting without major complications: these studies enroll hospitalized adults diagnosed with atypical myeloproliferative disorders or poorly differentiated neoplastic hematologic conditions who do not have CC/MCC-level complications, testing efficacy and safety of new molecularly targeted or immune-based agents compared with standard of care. Research objectives include measuring short-term hematologic response rates, toxicity profiles in the inpatient setting, and biomarkers predictive of response; findings inform inpatient treatment pathways and expected resource utilization relevant to payers.
- Comparative effectiveness studies of inpatient vs. early outpatient management strategies for stabilization and initiation of therapy in myeloproliferative disorders: pragmatic trials or observational cohort studies assess outcomes for patients admitted for symptomatic cytoses, anemia, or constitutional symptoms who are randomized or propensity-matched to receive initial stabilization and therapy during hospitalization versus expedited outpatient initiation with close follow-up. These studies target cost, readmission rates, complication incidence, and quality-of-life endpoints, providing evidence on optimal site-of-care decisions that directly affect hospital reimbursements and care coordination costs.
- Post-discharge outcomes and health services research focusing on readmission risk stratification and transitional care interventions for this population: cohort studies and interventional trials evaluate discharge planning models, outpatient monitoring intensity, and supportive-care pathways for patients discharged after treatment initiation or stabilization for other myeloproliferative disorders or poorly differentiated neoplasms. By identifying predictors of 30- and 90-day readmissions, adverse events, and outpatient resource use, this research helps providers develop risk-adjusted care pathways and helps payers design case management and bundled-payment strategies aligned with real-world outcomes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.